Short answer
When designing experiments or developing interventions involving chemogenetic tools, always include a control group that receives the actuator without the genetic modification to isolate the true effect of the intervention.
- Field
- Human Factors
- Source
- bioRxiv (Cold Spring Harbor Laboratory) (2022)
- Method
- Experimental study with physiological measurements
- Sample
- Not explicitly stated, but implied to be sufficient for statistical analysis of mouse groups.
- Evidence
- Strong effect
Commonly used chemogenetic actuators, such as CNO and C21, can significantly alter sleep architecture and physiology even in the absence of engineered receptors, suggesting potential unintended human factors implications in research and therapeutic applications. This human factors research insight is drawn from a 2022 study published in bioRxiv (Cold Spring Harbor Laboratory). Using Experimental study with physiological measurements with Not explicitly stated, but implied to be sufficient for statistical analysis of mouse groups., researchers explored how this design variable affects real-world outcomes. The key design takeaway: When designing experiments or developing interventions involving chemogenetic tools, always include a control group that receives the actuator without the genetic modification to isolate the true effect of the intervention.
Chemogenetic Actuators Can Induce Sleep Disturbances in Non-Targeted Subjects
Commonly used chemogenetic actuators, such as CNO and C21, can significantly alter sleep architecture and physiology even in the absence of engineered receptors, suggesting potential unintended human factors implications in research and therapeutic applications.
bioRxiv (Cold Spring Harbor Laboratory) · 2022
Key Findings
- 01Intraperitoneal injections of commonly used CNO doses (1, 5, and 10 mg/kg) altered sleep in wild-type mice.
- 02A dose-dependent suppression of REM sleep was observed with CNO.
- 03Changes in EEG spectral power during NREM sleep and altered sleep architecture were noted.
- 04The novel DREADD actuator, compound 21 (C21, 3 mg/kg), also modulated sleep, similar to CNO.
- 05These effects occurred in mice not expressing DREADD receptors, indicating off-target pharmacological actions.
Application
Design takeaway
When designing experiments or developing interventions involving chemogenetic tools, always include a control group that receives the actuator without the genetic modification to isolate the true effect of the intervention.
How to apply
In any research project involving chemogenetics, implement a control group that receives the actuator but lacks the DREADD receptors. Use electrophysiological sleep assessment as a sensitive method to detect potential side effects of novel actuators.
Project actions
- 01When designing an experiment with a new tool, think about what else that tool might do on its own.
- 02Consider how to measure unintended effects, like changes in behavior or physiology.
Method & Evidence
Variables
Strengths & Limitations
Strengths
- +Utilized gold-standard electrophysiological methods (EEG/EMG) for sleep analysis.
- +Investigated both a widely used and a novel chemogenetic actuator.
Limitations
The study was limited to male mice. The specific binding targets or metabolic pathways responsible for the observed sleep alterations were not fully elucidated.
Reliability & validity
The use of EEG/EMG provides high reliability and validity for sleep stage classification. The study's strength lies in its direct measurement of physiological sleep parameters. However, the generalizability to humans and the full elucidation of all off-target mechanisms may limit external validity.
Think critically
If a chemogenetic actuator has known off-target effects on sleep, how might this influence the interpretation of research findings related to memory consolidation or learning, which are known to be sleep-dependent?
Design Principles
"Pharmacological inertness of research tools should be rigorously validated, especially when studying sensitive physiological processes like sleep."
This finding is crucial for researchers and designers working with chemogenetic tools, as it highlights the need for rigorous control groups to isolate the effects of genetic manipulation from the inherent pharmacological actions of the actuators. Understanding these off-target effects is vital for accurate interpretation of research data and for the safe development of future interventions.
What This Means for Your Design
Even when you're trying to control specific cells with special chemicals (like CNO or C21), these chemicals can sometimes affect other parts of the body, like sleep, even if the cells you want to control aren't there. So, you need to test the chemical on its own to make sure it's not causing problems.
How to use in your project
- 1.Reference this study when discussing the importance of control groups in experiments involving biological interventions or pharmacological agents.
- 2.Use it to justify the inclusion of baseline measurements for physiological parameters that could be affected by the experimental intervention.
Add to My Project
Quick Cite
Paragraph starter
This research highlights the critical need for rigorous control groups in experimental design. The study by Traut et al. (2022) demonstrated that chemogenetic actuators like CNO and C21 can induce significant sleep disturbances in subjects lacking the target receptors, indicating inherent pharmacological activity. Therefore, any design project employing such agents must include a control group treated with the actuator alone to differentiate between the intended effect and unintended side effects, ensuring the validity of the findings.
Source
bioRxiv (Cold Spring Harbor Laboratory)
Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice
journal · 2022
View sourceQuestions About This Research
- What does the research say about chemogenetic actuators can induce sleep disturbances in non-targeted subjects?
- When designing experiments or developing interventions involving chemogenetic tools, always include a control group that receives the actuator without the genetic modification to isolate the true effect of the intervention. Evidence: bioRxiv (Cold Spring Harbor Laboratory) (2022).
- Why does "Chemogenetic Actuators Can Induce Sleep Disturbances in Non-Targeted Subjects" matter for design?
- This finding is crucial for researchers and designers working with chemogenetic tools, as it highlights the need for rigorous control groups to isolate the effects of genetic manipulation from the inherent pharmacological actions of the actuators. Understanding these off-target effects is vital for accurate interpretation of research data and for the safe development of future interventions.
- How can designers apply this research?
- When designing experiments or developing interventions involving chemogenetic tools, always include a control group that receives the actuator without the genetic modification to isolate the true effect of the intervention.
- What were the main findings?
- Intraperitoneal injections of commonly used CNO doses (1, 5, and 10 mg/kg) altered sleep in wild-type mice.. A dose-dependent suppression of REM sleep was observed with CNO.. Changes in EEG spectral power during NREM sleep and altered sleep architecture were noted.. The novel DREADD actuator, compound 21 (C21, 3 mg/kg), also modulated sleep, similar to CNO.
- What research method was used?
- Experimental study with physiological measurements with Not explicitly stated, but implied to be sufficient for statistical analysis of mouse groups..
- How strong is the evidence?
- Evidence strength is rated Strong effect, based on a 2022 journal from bioRxiv (Cold Spring Harbor Laboratory).
- What should I do differently in my next project?
- In any research project involving chemogenetics, implement a control group that receives the actuator but lacks the DREADD receptors. Use electrophysiological sleep assessment as a sensitive method to detect potential side effects of novel actuators.
- What are the limitations?
- The study was conducted on male laboratory mice, and findings may not directly translate to other species or sexes. The specific mechanisms of off-target action (e.g., back-metabolism to clozapine, binding to endogenous receptors) require further detailed investigation.